v3.24.0.1
Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended 30 Months Ended 33 Months Ended
Nov. 30, 2023
Oct. 31, 2023
Apr. 30, 2021
Dec. 31, 2023
Dec. 31, 2023
Dec. 31, 2023
May 10, 2023
Dec. 31, 2022
Nature Of Business And Basis Of Presentation [Line Items]                
Accumulated deficit       $ 1,189,889,000 $ 1,189,889,000 $ 1,189,889,000   $ 1,057,362,000
Cash, cash equivalents, and marketable securities       1,200,000,000 1,200,000,000 $ 1,200,000,000    
Jeffries LLC Amended Sales Agreement                
Nature Of Business And Basis Of Presentation [Line Items]                
Gross proceeds from issuance of common stock       $ 564,000,000 $ 564,000,000      
Jeffries LLC Amended Sales Agreement | Common Stock                
Nature Of Business And Basis Of Presentation [Line Items]                
Stock sold during period shares, new issues       10,860,992        
Public offering price per share       $ 51.93 $ 51.93 $ 51.93    
Jeffries LLC Amended Sales Agreement | ATM Offering                
Nature Of Business And Basis Of Presentation [Line Items]                
Aggregate gross proceeds of shares authorized under ATM sales agreement             $ 800,000,000  
Jeffries LLC Sales Agreement                
Nature Of Business And Basis Of Presentation [Line Items]                
Stock sold during period shares, new issues     2,908,009 2,908,009        
Public offering price per share       $ 103.16 $ 103.16 $ 103.16    
Gross proceeds from issuance of common stock     $ 300,000,000 $ 300,000,000        
Jeffries LLC Sales Agreement | Maximum | ATM Offering                
Nature Of Business And Basis Of Presentation [Line Items]                
Commission rate     3.00%          
Aggregate gross proceeds of shares authorized under ATM sales agreement     $ 300,000,000          
Jeffries LLC Sales Agreement and Amended Sales Agreement                
Nature Of Business And Basis Of Presentation [Line Items]                
Gross proceeds from issuance of common stock           $ 864,000,000    
Lilly Agreement                
Nature Of Business And Basis Of Presentation [Line Items]                
Stock purchase agreement amount received   $ 50,000,000            
Proceeds from potential future development-stage upfront payments   $ 200,000,000            
Collaboration agreement upfront payment received $ 200,000,000              
Sale and issuance of common stock   2,004,811            
Aggregated purchase price   $ 50,000,000            
Lilly Agreement | Maximum                
Nature Of Business And Basis Of Presentation [Line Items]                
Additional proceeds from potential future development-stage payments   $ 350,000,000